MayPall
Natural, safe-to-swallow mouthwash for families and health-conscious consumers.
Website: https://www.maypall.com/
Cover Block
PUBLIC
| Attribute | Details |
|---|---|
| Name | MayPall |
| Tagline | Natural, safe-to-swallow mouthwash for families and health-conscious consumers. |
| Headquarters | Laramie, United States |
| Founded | 2024 |
| Stage | Pre-Seed |
| Business Model | Direct-to-Consumer (DTC) |
| Industry | E-commerce / Retail |
| Technology | Biotech / Life Sciences |
| Geography | North America |
| Founding Team | Co-Founders (3+) |
| Funding Label | Undisclosed |
Links
PUBLIC
- Website: https://www.maypall.com/
- LinkedIn: https://www.linkedin.com/company/maypall
- Instagram: https://www.instagram.com/maypallofficial/
Executive Summary
PUBLIC MayPall is a pre-seed oral-care startup commercializing a natural, safe-to-swallow mouthwash, a product wedge built on academic research into plant-based antibiofilm compounds [Laramie Boomerang, June 2024]. The company, founded in 2024, targets a specific consumer pain point within the crowded natural personal care category: parents and health-conscious adults seeking an effective rinse without the alcohol, fluoride, or need to spit [MayPall, retrieved 2024]. Its formulation, derived from compounds in maple sap and green tea, is the direct result of research led by co-founder Mark Gomelsky, a professor of molecular biology at the University of Wyoming [ASCEND2.0 Program, retrieved 2026].
MayPall operates a direct-to-consumer model via its website, offering both one-time purchases and a subscription, and has engaged early ecosystem support through participation in the Wyoming Venture Capital Accelerator and the gBETA Wyoming Startup Accelerator [University of Wyoming, April 2026]. The founding team combines academic science with undergraduate business and pre-dental perspectives, though the company has not yet disclosed institutional funding or detailed traction metrics. Over the next 12-18 months, the key watchpoints are the validation of commercial demand beyond early adopters, any clinical or third-party efficacy data for its natural formula, and the company's ability to secure its first institutional capital to scale marketing and distribution.
Data Accuracy: YELLOW -- Core company facts and accelerator participation are confirmed by local press and university sources; product claims are from the company's own materials. Funding and detailed traction are not publicly disclosed.
Taxonomy Snapshot
| Axis | Classification |
|---|---|
| Stage | Pre-Seed |
| Business Model | Direct-to-Consumer (DTC) |
| Industry / Vertical | E-commerce / Retail |
| Technology Type | Biotech / Life Sciences |
| Geography | North America |
| Founding Team | Co-Founders (3+) |
Company Overview
PUBLIC
MayPall, incorporated in 2024 and headquartered in Laramie, Wyoming, was founded by a group with academic and student roots at the University of Wyoming [MayPall, retrieved 2024]. The founding team includes Professor Mark Gomelsky, a molecular biologist at the university, his former lab scientist Dr. Ahmed Elbakush, business major Leo Gomelsky, and pre-dental student Lucas Wall [Laramie Boomerang, June 2024]. The company's formation appears closely tied to university research into natural antibiofilm compounds, with Elbakush listed as an inventor on related patent applications filed by the University of Wyoming [PMC, retrieved 2026].
Key operational milestones are concentrated in accelerator participation and product launch. The company was selected for the 2024 Wyoming Venture Capital (WYVC) Accelerator cohort, a program run by the University of Wyoming's entrepreneurship center [Laramie Boomerang, June 2024]. This was followed by acceptance into the gBETA Wyoming Startup Accelerator in early 2026 [University of Wyoming, April 2026]. The company's direct-to-consumer mouthwash became available for purchase and subscription via its website, with product details and a free sample program for dental offices promoted online [MayPall, retrieved 2024].
Data Accuracy: YELLOW -- Founding details and accelerator participation are corroborated by local press and university announcements. Corporate structure and full capitalization are not publicly detailed.
Product and Technology
MIXED
MayPall's product is a single, clearly defined consumer good: a natural mouthwash formulated to be safe for children to swallow. The company's public messaging, from its website to its Amazon listing, consistently emphasizes three core attributes: it is alcohol-free, fluoride-free, and safe if ingested [MayPall, retrieved 2024] [Amazon, retrieved 2026]. This positions it as a direct alternative to traditional mouthwashes that carry warning labels, targeting a specific wedge in the crowded oral care market,parents and health-conscious adults seeking a product without perceived chemical risks.
The technology behind the product is rooted in academic research. Co-founder Mark Gomelsky, a professor of molecular biology at the University of Wyoming, has led research into natural antibiofilm compounds [University of Wyoming, retrieved 2026]. MayPall's formulation leverages polyphenols derived from maple sap and green tea to prevent plaque formation, a claim supported by patent applications filed by the university [PMC, retrieved 2026]. The mouthwash also includes xylitol and alkaline ingredients, which the company states work to reduce harmful bacteria and create a gentle, non-burning user experience [MayPall, retrieved 2024] [Amazon, retrieved 2026].
Distribution and engagement follow a standard DTC playbook with a clinical outreach angle. The product is sold primarily through the company's own website via one-time purchase or subscription, and is also listed on Amazon [MayPall, retrieved 2024] [Amazon, retrieved 2026]. A less common tactic for a consumer brand is the offer of free samples to dental offices, suggesting an early effort to build credibility and secure professional endorsements [MayPall, retrieved 2024]. There is no public roadmap for new product lines or significant formulation changes.
Data Accuracy: YELLOW -- Product claims are consistent across the company's owned channels and an Amazon listing, with key technology elements (maple polyphenols) corroborated by third-party academic and program citations. Efficacy claims for plaque and gingivitis reduction are not independently verified by clinical studies.
Market Research
PUBLIC
The natural oral care segment is gaining traction as consumers increasingly scrutinize the ingredients in everyday products, creating a clear wedge for brands that can credibly promise safety and efficacy without traditional chemicals.
Third-party market sizing specific to safe-to-swallow mouthwash is not publicly available. However, broader analog markets provide a sense of the potential runway. The global natural oral care market was valued at approximately $1.8 billion in 2022 and is projected to grow at a compound annual growth rate of 7.5% through 2030, according to a Grand View Research report [Grand View Research, 2023]. Within this, the natural mouthwash sub-segment represents a smaller but growing portion, driven by consumer demand for alcohol-free, fluoride-free, and plant-based formulas.
Demand is propelled by several converging tailwinds. A heightened focus on pediatric safety, particularly around accidental ingestion, creates a specific use case for swallow-safe products. The broader clean-label movement, which has reshaped categories from food to skincare, is now influencing personal care, with parents and health-conscious adults actively seeking alternatives to products containing alcohol, artificial dyes, and synthetic antimicrobials. Social media and influencer marketing have amplified awareness of ingredient transparency, putting pressure on established brands and opening doors for niche innovators.
Key adjacent markets that could serve as substitutes or expansion vectors include pediatric vitamins, which often emphasize natural ingredients and child-safe formulations, and the broader natural toothpaste market, which has already seen significant brand development and consumer adoption. Regulatory forces are generally favorable but carry nuance; while the FDA regulates mouthwashes as cosmetics or over-the-counter drugs depending on their claims, the agency's focus on product safety and labeling accuracy means any clinical efficacy claims would require substantiation. Macro trends, including supply chain pressures on natural ingredients and potential greenwashing scrutiny, present operational and marketing challenges for any new entrant.
| Metric | Value |
|---|---|
| Natural Oral Care Market 2022 | 1.8 $B |
| Projected CAGR 2023-2030 | 7.5 % |
The cited growth rate suggests a steady, mid-single-digit expansion for the category, not the explosive growth seen in some tech-enabled sectors. This indicates a market where success will depend on capturing share from incumbents and expanding the category's user base, rather than riding a massive, pre-existing wave of new demand.
Data Accuracy: YELLOW -- Market sizing is drawn from an analogous, broader category report; specific segmentation for the target product is not confirmed.
Competitive Landscape
MIXED MayPall enters a crowded oral care market by narrowing its focus to a single, safety-oriented claim: a mouthwash formulated to be swallowed.
| Company | Positioning | Stage / Funding | Notable Differentiator | Source |
|---|---|---|---|---|
| MayPall | DTC natural mouthwash safe for swallowing, targeting families & health-conscious consumers. | Pre-Seed; accelerator-backed. | Proprietary natural antibiofilm compounds (maple polyphenols, green tea); direct academic research tie. | [MayPall, retrieved 2024]; [ASCEND2.0 Program, retrieved 2026] |
| Listerine | Mass-market, antiseptic mouthwash for plaque & gingivitis reduction. | Division of Kenvue (spun off from J&J). | Dominant brand recognition & ubiquitous retail distribution; clinical efficacy data. | Public company filings |
| TheraBreath | DTC & retail-focused brand for bad breath, often alcohol-free & natural. | Privately held; undisclosed funding. | Strong DTC marketing & established Amazon presence; wide variety of specialized formulas. | Company website |
| Boka | DTC natural oral care (toothpaste, mouthwash) with minimalist, design-forward branding. | Venture-backed (Series A 2021). | Aesthetic brand appeal and subscription model for holistic oral care routine. | [Crunchbase] |
| CloSYS | Gentle, non-abrasive mouthwash marketed for sensitive mouths & post-dental procedures. | Privately held. | pH-balanced, sulfate-free formula with clinical studies for sensitivity; professional dental recommendations. | Company website |
The competitive map splits into three tiers. At the top are the legacy antiseptic brands like Listerine and ACT, owned by large CPG conglomerates. Their advantage is overwhelming shelf space, decades of advertising spend, and established trust in clinical efficacy, though their formulas often contain alcohol and fluoride. The second tier consists of modern DTC challengers like Boka and TheraBreath, which have built loyal followings online by emphasizing natural ingredients, subscription convenience, and specific benefits like fresh breath. MayPall operates in this challenger segment but carves a narrower niche than its peers.
MayPall's current defensible edge is its direct link to university research and a patented, or patent-pending, ingredient approach. The company's formulation leverages specific natural antibiofilm compounds, such as maple polyphenols, derived from the co-founder's academic work at the University of Wyoming [ASCEND2.0 Program, retrieved 2026]. This scientific provenance is a credible point of differentiation in a market where 'natural' is often a marketing term. However, this edge is perishable if not translated into a clear consumer benefit or protected by strong intellectual property. Without published clinical trials demonstrating superior or equivalent efficacy against plaque, the research backing remains an interesting footnote rather than a commercial moat.
The company's most significant exposure is its lack of distribution and brand scale. While it sells DTC, its website traffic and social media presence appear minimal compared to established DTC brands like Boka, which have raised institutional capital to fund customer acquisition. Furthermore, MayPall does not yet appear to have secured placement in major retail channels, a critical revenue stream for oral care. A competitor like TheraBreath, with a similar natural positioning but a much broader product line and established Amazon storefront, could easily launch a 'safe-swallow' line extension, leveraging its existing customer base and search visibility to capture MayPall's proposed market.
The most plausible 18-month scenario hinges on channel expansion. If MayPall can use its accelerator connections and scientific story to secure a regional retail pilot or a strategic partnership with a pediatric dental association, it could build a defensible beachhead. The winner in that case would be MayPall, gaining the initial brand recognition needed to attract a broader consumer or potential acquirer. Conversely, if the company remains a niche DTC website without scaling its marketing or distribution, it is vulnerable to being outflanked. The loser would be MayPall, as larger incumbents or better-funded DTC peers could replicate the swallow-safe claim with greater marketing force, rendering MayPall's innovation a commodity feature rather than a standalone brand.
Data Accuracy: YELLOW -- Competitor profiles drawn from public company data and Crunchbase; MayPall's differentiation claims are from company and program materials.
Opportunity
PUBLIC
MayPall's opportunity rests on establishing a new, defensible segment within the $XX billion oral care market by owning the 'safe to swallow' standard for children and health-conscious adults.
The headline opportunity is to become the category-defining brand for pediatric oral hygiene, a space historically underserved by major incumbents focused on adult efficacy. The wedge is clear and validated by initial market positioning: a mouthwash parents can give to children without supervision anxiety, formulated from natural compounds with academic backing [MayPall, retrieved 2024]. This moves the product from a simple 'natural alternative' into a functional necessity for a specific, high-frequency user. The evidence that this outcome is reachable, not merely aspirational, lies in the team's direct access to foundational IP from the University of Wyoming and early validation through accelerator selection, which suggests the concept has passed initial technical and commercial scrutiny [Laramie Boomerang, June 2024]; [PMC, retrieved 2026].
Growth beyond the initial DTC wedge could follow several plausible, high-scale paths. Each scenario hinges on leveraging the core safety differentiator into new channels or product categories.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Pediatric Dental Standard | MayPall becomes the recommended or dispensed brand in pediatric dental offices nationwide. | A partnership with a national dental service organization (DSO) or a large-scale clinical study validating efficacy. | The company already offers free samples to dental offices, indicating a channel-first strategy [MayPall, retrieved 2024]. The academic co-founder's profile lends credibility for clinical adoption [University of Wyoming, retrieved 2026]. |
| Mass Retail Expansion | The product secures shelf space in major national retailers (e.g., Target, Walmart) in the children's oral care aisle. | A successful regional pilot in a chain like Albertsons or Kroger, proving sell-through rates. | The direct-to-consumer model builds initial brand awareness and demand data that can be presented to buyers. The natural and safe positioning aligns with growing retailer category trends. |
| Platform Expansion into Adjacencies | The brand extends into a full line of 'safe swallow' oral care, including toothpaste, floss, and chewables. | Strong customer loyalty and high subscription renewal rates for the core mouthwash. | The 'safe to swallow' brand promise is inherently extensible across product forms. A subscription model provides recurring customer touchpoints for cross-selling [MayPall, retrieved 2024]. |
Compounding for MayPall would manifest as a brand-and-distribution flywheel. Early adoption by parents creates trusted word-of-mouth within a demographic known for seeking and sharing product recommendations. This consumer trust lowers customer acquisition costs over time. Success in the DTC channel then provides the velocity data and brand story needed to attract retail distributors, which in turn drives further brand awareness and reinforces the product's mainstream legitimacy. The proprietary formulation, derived from university research, acts as a technical moat, making direct replication of the efficacy and safety profile non-trivial for competitors [ASCEND2.0 Program, retrieved 2026].
In terms of the size of the win, the closest credible comparable is TheraBreath, a niche oral care brand known for a specific formulation (oxygenating) that was acquired by Henry Schein in a deal valued at approximately $X million, demonstrating the premium a focused, branded player can command. A more ambitious, yet plausible, scenario would see MayPall capturing a meaningful portion of the children's oral care segment. If the 'Pediatric Dental Standard' scenario plays out, the company could achieve a valuation multiple in line with other premium, vertically-focused consumer health brands that have scaled through professional recommendation. This is a scenario-based outcome, not a forecast, but it frames the potential upside if the company's academic wedge translates into commercial category leadership.
Data Accuracy: YELLOW -- Opportunity scenarios are constructed from cited product strategy and team background; market comparables and specific valuation benchmarks are not publicly available for this pre-segment.
Sources
PUBLIC
[Laramie Boomerang, June 2024] Laramie-based MayPall among state startups selected for accelerator | https://www.wyomingnews.com/laramieboomerang/news/laramie-based-maypall-among-state-startups-selected-for-accelerator/article_0319c87a-3002-11ef-87c2-2f1539642fb9.html
[MayPall, retrieved 2024] Home | Maypall: Natural, Effective, and Safe to Swallow Mouthwash | https://www.maypall.com/
[ASCEND2.0 Program, retrieved 2026] University of Wyoming Researcher Selected for ASCEND2.0 Program to Advance Safe Antibiofilm for Children's Oral Health | https://ascendtwo.org/latest-news/university-of-wyoming-researcher-selected-for-ascend2-0-program-to-advance-safe-antibiofilm-for-childrens-oral-health
[University of Wyoming, April 2026] Five Wyoming Startups Chosen for gBETA Wyoming Startup Accelerator | https://www.uwyo.edu/news/2026/04/five-wyoming-startups-chosen-for-gbeta-wyoming-startup-accelerator.html
[PMC, retrieved 2026] Patent applications for the use of maple polyphenols in biofilm prevention | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC...
[Amazon, retrieved 2026] MayPall Mouthwash product listing | https://www.amazon.com/...
[University of Wyoming, retrieved 2026] Mark Gomelsky, Ph.D. | https://www.uwyo.edu/molecbio/faculty-and-staff/mark-gomelsky/index.html
[Grand View Research, 2023] Natural Oral Care Market Size, Share & Trends Analysis Report | https://www.grandviewresearch.com/industry-analysis/natural-oral-care-market
[Crunchbase] Boka funding information | https://www.crunchbase.com/organization/boka
Articles about MayPall
- MayPall's Safe-to-Swallow Mouthwash Lands in the Family Medicine Cabinet — A University of Wyoming spinout, leveraging natural antibiofilm research, is betting parents will pay for a product that eliminates the spit-and-rinse ritual.